Recruiting
Phase 3

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Sponsor:

AB Science

Code:

NCT03127267

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Masitinib (6.0)

Riluzole

Placebo

Masitinib (4.5)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information